AUA Updates Prostate Cancer Guidelines with Risk-Based Management Refinements

Event summary

  • The American Urological Association (AUA) released the 2026 amendment to its Clinically Localized Prostate Cancer Guideline on April 16, 2026.
  • The update includes 46 recommendations, focusing on risk-based management, imaging, radiation therapy, and shared decision-making.
  • New guidance covers hormonal therapy sequencing for intermediate-risk prostate cancer and treatment intensification for very high-risk cases.
  • The full guideline is available at Auanet.org/ProstateCancerGuideline2026.

The big picture

The AUA's guideline amendment reflects the evolving landscape of prostate cancer care, emphasizing evidence-based, personalized treatment approaches. This update aligns with broader trends in precision medicine and shared decision-making, potentially influencing reimbursement policies and clinical workflows. The collaboration with ASTRO underscores the importance of multidisciplinary consensus in managing localized prostate cancer.

What we're watching

Guideline Adoption
How quickly healthcare providers integrate the updated recommendations into clinical practice.
Treatment Innovation
The pace at which new data on hormonal therapy and radiation therapy influences future guideline amendments.
Patient Outcomes
Whether the refined risk-based management system improves individualized care and treatment outcomes.